

**Experiment Number:** 88073-04  
**Test Type:** 26-WEEK  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS  
ABRIDGED) (a)**

**Test Compound:** 2',3'-Dideoxycytidine  
**CAS Number:** 7481-89-2

**Date Report Requested:** 10/18/2014  
**Time Report Requested:** 15:29:22  
**First Dose M/F:** NA / NA  
**Lab:** SRI

<b>C Number:</b>	C88073C
<b>Lock Date:</b>	07/25/1995
<b>Cage Range:</b>	All
<b>Date Range:</b>	All
<b>Reasons For Removal:</b>	All
<b>Removal Date Range:</b>	All
<b>Treatment Groups:</b>	All
<b>Study Gender:</b>	Both
<b>PWG Approval Date</b>	NONE

Experiment Number: 88073-04  
 Test Type: 26-WEEK  
 Route: GAVAGE  
 Species/Strain: Mouse/B6C3F1

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**

Test Compound: 2',3'-Dideoxycytidine  
 CAS Number: 7481-89-2

Date Report Requested: 10/18/2014  
 Time Report Requested: 15:29:22  
 First Dose M/F: NA / NA  
 Lab: SRI

B6C3F1 Mouse MALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
<b>Disposition Summary</b>				
Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice		1		
Survivors				
Terminal Sacrifice	50	49	50	50
Animals Examined Microscopically	50	50	50	50
<b>ALIMENTARY SYSTEM</b>				
Liver	(50)	(50)	(50)	(50)
<b>CARDIOVASCULAR SYSTEM</b>				
None				
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(49)	(50)	(49)	(49)
Adrenal Medulla	(49)	(50)	(49)	(49)
<b>GENERAL BODY SYSTEM</b>				
None				
<b>GENITAL SYSTEM</b>				
None				
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Lymph Node	(0)	(0)	(1)	(0)
Lymph Node, Mesenteric	(49)	(50)	(50)	(50)
Spleen	(50)	(50)	(50)	(50)
Thymus	(49)	(50)	(49)	(50)
<b>INTEGUMENTARY SYSTEM</b>				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

**Experiment Number:** 88073-04  
**Test Type:** 26-WEEK  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**  
**Test Compound:** 2',3'-Dideoxycytidine  
**CAS Number:** 7481-89-2

**Date Report Requested:** 10/18/2014  
**Time Report Requested:** 15:29:22  
**First Dose M/F:** NA / NA  
**Lab:** SRI

B6C3F1 Mouse MALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
Skin	(0)	(0)	(0)	(1)
Squamous Cell Papilloma				1 (100%)
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
Kidney	(0)	(0)	(1)	(0)
SYSTEMIC LESIONS				
Multiple Organ	*(50)	*(50)	*(50)	*(50)
Lymphoma Malignant		3 (6%)	8 (16%)	4 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

Experiment Number: 88073-04  
 Test Type: 26-WEEK  
 Route: GAVAGE  
 Species/Strain: Mouse/B6C3F1

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**  
 Test Compound: 2',3'-Dideoxycytidine  
 CAS Number: 7481-89-2

Date Report Requested: 10/18/2014  
 Time Report Requested: 15:29:22  
 First Dose M/F: NA / NA  
 Lab: SRI

B6C3F1 Mouse MALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
<b>Tumor Summary for MALE</b>				
Total Animals with Primary Neoplasms (b)	1	4	9	6
Total Primary Neoplasms	1	4	9	6
Total Animals with Benign Neoplasms	1	1	1	2
Total Benign Neoplasms	1	1	1	2
Total Animals with Malignant Neoplasms		3	8	4
Total Malignant Neoplasms		3	8	4
Total Animals with Metastatic Neoplasms				
Total Metastatic Neoplasms				
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain - Benign or Malignant				
Total Uncertain Neoplasms				

\*\*\*END OF MALE DATA\*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

Experiment Number: 88073-04  
 Test Type: 26-WEEK  
 Route: GAVAGE  
 Species/Strain: Mouse/B6C3F1

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**

Test Compound: 2',3'-Dideoxycytidine  
 CAS Number: 7481-89-2

Date Report Requested: 10/18/2014  
 Time Report Requested: 15:29:22  
 First Dose M/F: NA / NA  
 Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
<b>Disposition Summary</b>				
Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice			3	4
Natural Death				1
Survivors				
Moribund Sacrifice				1
Terminal Sacrifice	50	50	47	44
Animals Examined Microscopically	50	50	50	50
<b>ALIMENTARY SYSTEM</b>				
Liver	(50)	(50)	(50)	(50)
Mesentery	(0)	(0)	(0)	(1)
Pancreas	(0)	(0)	(0)	(1)
<b>CARDIOVASCULAR SYSTEM</b>				
None				
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(49)	(50)	(50)	(50)
Adrenal Medulla	(48)	(50)	(50)	(50)
<b>GENERAL BODY SYSTEM</b>				
None				
<b>GENITAL SYSTEM</b>				
Ovary	(50)	(50)	(50)	(50)
Uterus	(7)	(7)	(6)	(1)
Polyp Stromal		1 (14%)	3 (50%)	
<b>HEMATOPOIETIC SYSTEM</b>				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

**Experiment Number:** 88073-04  
**Test Type:** 26-WEEK  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**

**Test Compound:** 2',3'-Dideoxycytidine  
**CAS Number:** 7481-89-2

**Date Report Requested:** 10/18/2014  
**Time Report Requested:** 15:29:22  
**First Dose M/F:** NA / NA  
**Lab:** SRI

B6C3F1 Mouse FEMALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
Bone Marrow	(50)	(50)	(50)	(50)
Lymph Node	(1)	(0)	(3)	(2)
Lymph Node, Mandibular	(0)	(0)	(2)	(4)
Lymph Node, Mesenteric	(50)	(50)	(50)	(49)
Spleen	(50)	(50)	(50)	(50)
Thymus	(50)	(50)	(50)	(49)
<b>INTEGUMENTARY SYSTEM</b>				
Skin	(0)	(2)	(3)	(2)
<b>MUSCULOSKELETAL SYSTEM</b>				
None				
<b>NERVOUS SYSTEM</b>				
Brain	(0)	(0)	(0)	(1)
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma				1 (2%)
<b>SPECIAL SENSES SYSTEM</b>				
None				
<b>URINARY SYSTEM</b>				
Kidney	(0)	(0)	(2)	(4)
<b>SYSTEMIC LESIONS</b>				
Multiple Organ	*(50)	*(50)	*(50)	*(50)
Lymphoma Malignant		1 (2%)	24 (48%)	19 (38%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

Experiment Number: 88073-04  
Test Type: 26-WEEK  
Route: GAVAGE  
Species/Strain: Mouse/B6C3F1

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS  
ABRIDGED) (a)**  
Test Compound: 2',3'-Dideoxycytidine  
CAS Number: 7481-89-2

Date Report Requested: 10/18/2014  
Time Report Requested: 15:29:22  
First Dose M/F: NA / NA  
Lab: SRI

---

B6C3F1 Mouse FEMALE	VEHICLE	500	MG/KG/DY	1000	MG/KG/DY	1000	MG/KG/DY
<b>Tumor Summary for FEMALE</b>							
Total Animals with Primary Neoplasms (b)		2		26		20	
Total Primary Neoplasms		2		27		20	
Total Animals with Benign Neoplasms		1		3		1	
Total Benign Neoplasms		1		3		1	
Total Animals with Malignant Neoplasms		1		24		19	
Total Malignant Neoplasms		1		24		19	
Total Animals with Metastatic Neoplasms							
Total Metastatic Neoplasms							
Total Animals with Malignant Neoplasms Uncertain Primary Site							
Total Animals with Neoplasms Uncertain - Benign or Malignant							
Total Uncertain Neoplasms							

---

**\*\* END OF REPORT \*\***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically